Targeting hydrogen sulfide (H2S) pathways offers a promising therapeutic approach to modulate matrix metalloproteinase (MMP) and CD147/EMMPRIN activity, thereby addressing key aspects of atherosclerosis progression and plaque stability (Figure 1). Here, BSG is linked to atherosclerosis.